Research programme: protein serine threonine kinase inhibitors - Myrexis
Alternative Names: MPI-0485520; MPI-485520Latest Information Update: 26 Nov 2012
At a glance
- Originator Myriad Pharmaceuticals
 - Developer Myrexis
 - Class Small molecules
 - Mechanism of Action I-kappa B kinase inhibitors; Protein-serine-threonine kinase inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - Available For Licensing Yes - Cancer; Inflammation; Rheumatoid arthritis
 
Highest Development Phases
- Suspended Cancer; Diabetes mellitus; Inflammation; Obesity; Rheumatoid arthritis; Systemic lupus erythematosus